



COURSE OF GUBRA A/S' ANNUAL GENERAL MEETING 2026

On Thursday, 26 March 2026 at 10:00 am (CET), the annual general meeting of Gubra A/S (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm, with the following agenda:

1. The board of directors' report on the Company's activities during the past financial year

2. Presentation of the audited annual report for adoption

3. Resolution on the appropriation of profit or payment of loss in accordance with the adopted annual report

4. Presentation of and advisory vote on the remuneration report

5. Proposal from the board of directors to approve the company's remuneration policy

6. Approval of remuneration of the board of directors for the current financial year

7. Election of members to the board of directors

8. Election of auditor

9. Authorisation to acquire treasury shares

10. Proposal from the board of directors to renew and increase the existing authorisation to issue warrants

11. Proposal from the board of directors to remove articles 6.5 and 6.5.1 of the Company's articles of association

12. Any proposals from the shareholders

13. Authorisation to the chairman of the general meeting

14. Any other business



Re item 1

The general meeting acknowledged the report of the board of directors on the Company's activities during the past financial year.

Re item 2

The general meeting adopted the 2025 annual report.

Re item 3

The general meeting approved the proposal to carry forward the result of the year as recorded in the adopted annual report to the following financial year.

Re item 4

The general meeting approved the Company's remuneration report by advisory vote.

Re item 5

The general meeting approved the Company's remuneration policy.

Re item 6

The general meeting approved the proposed remuneration of the board of directors for the current financial year. The remuneration level is slightly increased compared to 2025 as presented under agenda item 6 in the notice convening the annual general meeting.

Re item 7

The general meeting approved the re-election of [Monika Lessl](#), [Alexander Thomas Martensen-Larsen](#), Niels Vrang, [Jacob Jelsing](#), [Astrid Haug](#), Claudia Mitchell and [Arndt Justus Georg Schottelius](#).

The board of directors has re-elected Monika Lessl as chair of the board of directors and [Alexander Thomas Martensen-Larsen](#) as deputy chair of the board of directors.

Re item 8

The general meeting approved the re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC) as the Company's auditor for financial purposes.

Re item 9

No proposal had been made under this agenda item, as the board of directors in connection with the IPO was authorised in the period until 14 March 2028 to approve the acquisition of treasury shares, on one or more occasions, with a total nominal value of up to 10% of the share capital of the Company. The consideration may not deviate more than 10% from the official price quoted on Nasdaq Copenhagen A/S at the time of the acquisition.

Re item 10

The general meeting approved to renew and increase the existing authorisation to issue warrants as presented under agenda item 10 in the notice convening the annual general meeting.



Re item 11

The general meeting approved to remove articles 6.5 and 6.5.1 of the Company's articles of association as presented under agenda item 11 in the notice convening the annual general meeting.

Re item 12

No proposals from shareholders had been submitted.

Re item 13

The general meeting authorised the chairman of the general meeting to register the resolutions with the Danish Business Authority.

Contacts at Gubra

Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)

Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Emma Jappe Lange (ejl@gubra.dk, +45 5361 6755)

About Gubra

Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra's activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around \$400 million) in 2025. See www.gubra.dk for more information.

Attachments

[COURSE OF GUBRA A/S' ANNUAL GENERAL MEETING 2026](#)